MacroGenics, Inc. (MGNX) has received clearance from the U.S. FDA to lift the partial clinical hold on its Phase 2 LINNET study of Lorigerlimab, a bispecific DART molecule targeting ovarian and clear cell gynecologic cancers. The hold was initially imposed due to serious safety events, including fatalities among trial participants. With the hold now lifted, MacroGenics plans to resume patient enrollment under a revised protocol that incorporates enhanced safety measures.

This development is significant for the biopharmaceutical sector, particularly for investors monitoring clinical-stage companies. The resumption of the LINNET study could potentially lead to new insights into Lorigerlimab’s efficacy and safety, impacting the stock’s performance. Despite a slight decline in total revenue and a widening net loss for 2025, MacroGenics maintains a healthy cash position expected to sustain operations through late 2027.

Investors should watch MGNX closely as the company moves forward with the revised trial, as positive results could bolster stock performance and investor confidence in its oncology pipeline.

Source: nasdaq.com